With the emergence of drugs that target specific molecular alterations in the tumour, genomics has practically entered the oncology clinic.
Molecularly targeted agents have followed the same clinical development as cytotoxic agents and have been developed in selected tumour types. The occurrence of the same molecular alterations across various tumour types is well described.
This raises the question: should treatment decisions in the future be entirely based on molecular biology?
Get Christophe's presentation in seconds.
Fill in the form opposite.